Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma
| Autor: | Gustaf Ljungman, Beate Timmermann, Rudolf Hagen, Stefanie Kube, Daniel Kosztyla, Rupert Handgretinger, Simone Feuchtgruber, Thomas Klingebiel, Tobias M. Dantonello, Felix Niggli, Ruth Ladenstein, Monika Stark, Bernarda Kazanowska, Ewa Koscielniak, Jörg Fuchs, Barbara Selle, Stefan S. Bielack, Christin Linderkamp |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Multivariate analysis Hematology business.industry Surrogate endpoint medicine.medical_treatment Induction chemotherapy medicine.disease Surgery Internal medicine Pediatrics Perinatology and Child Health medicine Embryonal rhabdomyosarcoma business Rhabdomyosarcoma Progressive disease |
| Zdroj: | Pediatric Blood & Cancer. 62:16-23 |
| ISSN: | 1545-5009 |
| Popis: | Background Response (tumour volume reduction) to induction chemotherapy has been used to stratify secondary local and systemic treatment of Intergroup Rhabdomyosarcoma Study Group III (IRSG-III) embryonal rhabdomyosarcoma (RME) in consecutive CWS-trials. To evaluate its actual impact we studied response-related treatment and outcomes. Procedure Patients with IRSG-III RME 10 years, tumour size >5 cm and therapy in older trials. After response assessment n = 24 NR continued to receive induction chemotherapy, n = 32 received other combinations and n = 3 no further chemotherapy. Forty-two non-responders were irradiated, and the tumours were completely resected in n = 20. After a median follow-up of 8 years, 34 NR are alive. Seventeen of 21 failures leading to disease-related deaths were locoregional. The five-year overall survival rate (OS) was 76 ± 4% for PAR, 79 ± 14% for OR, but only 40 ± 19% for SPD (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text